» Authors » Traci Turner

Traci Turner

Explore the profile of Traci Turner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 988
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Raal F, Mehta V, Kayikcioglu M, Blom D, Gupta P, Elis A, et al.
Lancet Diabetes Endocrinol . 2025 Jan; 13(3):178-187. PMID: 39870096
Background: Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibep and evolocumab in...
2.
Gaudet D, Greber-Platzer S, Reeskamp L, Iannuzzo G, Rosenson R, Saheb S, et al.
Eur Heart J . 2024 Jun; 45(27):2422-2434. PMID: 38856678
Background And Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH...
3.
Martin S, Ditmarsch M, Simmons M, Alp N, Turner T, Davidson M, et al.
Eur Heart J Cardiovasc Pharmacother . 2022 Oct; 9(2):148-155. PMID: 36307922
Aims: Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. We aimed to compare accuracy of three clinically-implemented LDL-C equations in a clinical trial of cholesterol ester transfer protein...
4.
Nissen S, Wolski K, Balog C, Swerdlow D, Scrimgeour A, Rambaran C, et al.
JAMA . 2022 Apr; 327(17):1679-1687. PMID: 35368052
Importance: Lipoprotein(a) (Lp[a]) is an important risk factor for atherothrombotic cardiovascular disease and aortic stenosis, for which there are no treatments approved by regulatory authorities. Objectives: To assess adverse events...
5.
Raal F, Kallend D, Ray K, Turner T, Koenig W, Wright R, et al.
N Engl J Med . 2020 Mar; 382(16):1520-1530. PMID: 32197277
Background: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin...
6.
Kapuganti A, Turner T, Thomas C
Ment Health Clin . 2018 Jun; 7(6):271-275. PMID: 29955533
Introduction: This retrospective cohort study evaluated effects of buprenorphine/naloxone dose and concomitant use of selected sedating medications on treatment outcomes in patients with opioid use disorder. Methods: Patients enrolled in...
7.
8.
Braamskamp M, Langslet G, McCrindle B, Cassiman D, Francis G, Gagne C, et al.
Circulation . 2017 Jun; 136(4):359-366. PMID: 28592434
Background: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Children with HeFH exhibit early signs of atherosclerosis manifested by increased carotid intima-media thickness (IMT). In...
9.
Ray K, Landmesser U, Leiter L, Kallend D, Dufour R, Karakas M, et al.
N Engl J Med . 2017 Mar; 376(15):1430-1440. PMID: 28306389
Background: In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low-density...
10.
Braamskamp M, Langslet G, McCrindle B, Cassiman D, Francis G, Gagne C, et al.
J Clin Lipidol . 2015 Dec; 9(6):741-750. PMID: 26687694
Objective: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Guidelines recommend initiating statins early to reduce low-density lipoprotein cholesterol (LDL-C). Studies have evaluated rosuvastatin in...